General Annual 1 November 30, 2009 Meeting Disclaimer and - - PDF document

1

Annual General Meeting

November 30, 2009

Disclaimer and Important Notice

This presentation has been prepared by Unilife Medical Solutions Limited and its subsidiaries (Unilife).The material that follows is a presentation of general background information about Unilife's activities current at the date of the development of the presentation, p g g p p , November 30, 2009.It is information given in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential customers and partners and does not take into account the commercial objectives, financial situation or needs

• f any potential partner Readers should seek their own independent professional advice Statements contained in this presentation
• f any potential partner. Readers should seek their own independent professional advice. Statements contained in this presentation

may contain information relating to Unilife's financial condition, results of operations, business strategies, operating efficiencies, competitive position, growth opportunities for existing products and services, plans and objectives of management and other

• matters. These statements are estimates reflecting the best judgement of senior management of Unilife and involve a number of

risks and uncertainties that could cause actual results to differ materially from those suggested. Nothing contained in this presentation shall constitute an offer to sell or a solicitation of an offer to buy any securities of Unilife in any jurisdiction Unilife does not give any warranty in relation to the contents of this presentation and disclaims all or any liability for claims which may be made by any person acting or omitting to act, on the basis of any representations arising out of or in connection with this presentation.

1

5

Best-in-class innovative safety

medical devices ISO-13485 certified with strong automated assembly expertise Global HQ’s at FDA-registered facility in Pennsylvania (PA)

World-class team with device and

pharmaceutical expertise Pharmaceutical and healthcare industry leaders

Unilife in 2009

Overview

6

April 09 Complete transition of Unilife HQ to the US June 09 Industrialisation Agreement with sanofi-aventis Aug 09 Starts US production Unitract 1mL Syringes Sep 09 Proposes redomiciliation to US and NASDAQ Oct 2009 Receipt A$5.6m package from PA Government Nov 2009 Filed IM (ASIC) and Form 10 (SEC) documents Nov 2009 Completes $53.6m capital raising Nov 2009 Appoints Unifill assembly line partner Nov 2009 Files patents for new pipeline prefilled syringe

Key delivered milestones

Unilife in 2009

7

Corporate Position

Unilife in 2009

Transition of key functions to PA Foundations of world-class team 100 staff across three continents Doubled in size since 2008 40 managers, professionals added Average 23 years experience Strong industry backgrounds

8

Operational Position

Unilife in 2009

No longer a technology company Now an industrial manufacturer ISO-13485 certified Quality Management System FDA-registered facility Automated assembly expertise

9

Unilife in 2009

Relationship with sanofi-aventis Largest purchaser of prefilled syringes in the world Global leader in vaccines Largest pharmaceutical group in Europe One of the top five pharmaceutical groups in the world Six year relationship with Unilife

10

Key Terms of Agreements with sanofi-aventis

Signed Exclusive Agreement in June 2008

Payment of A$16.4m (€10m) on signing of Exclusive Agreement Industrialisation program with quarterly milestone payments Milestone payments of €11.5m to date (€5.5m still to come)

Signed Industrialisation Agreement in July 2009

Committed to fund industrialisation program A$30.4m (€17m) Retained right to sell to other customers in therapeutic classes to be agreed by both parties

Unilife in 2009

11

Financial Position A$40.4m in revenue A$12.8m net profit after tax A$53.6m capital raising

A$32.1m Private Placement A$21.5m Share Purchase Plan

A$50m cash balance (25/11/09)

Unilife in 2009

12

Unsafe injection practices 1.3m deaths a year from unsafe injections* 600,000 US healthcare workers incur a needlestick injury each year More than 50% of injections in developing countries are unsafe * 1/3 of HIV cases outside Sub-Saharan Africa from injecting drug use^ Community risk from unsafe disposal

+ International Association of Safe Injection Technologies (2004)

• World Health Organization

^ UNAIDS

Global transition to safety syringes

13

Federal Needlestick Prevention Act Strict enforcement by OSHA 1 in 5 OSHA-inspected facilities receive citation for non-compliance Passive, integrated safety features desired but few available Canada, EU, Australia following the US towards mandatory use

Global transition to safety syringes

The US Experience

14

Global transition to safety syringes

Awaiting products of choice

0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 1999 2000 2001 2002 2003 2004 2005 2006 2007

NSI by syringe / total NSIs NSI involved safety device

US reported needlestick injuries (1999 – 2007)

Syringes responsible for one-third of all injuries Safety devices now cause majority of all injuries

Source – EPINET - IHWSC

15

Pharmaceutical Companies Healthcare Facilities Diabetes Harm Reduction Other

Key Markets

Global transition to safety syringes

Market driven solutions: A round peg for a round hole

16

Unilife Products

Core Technology Passive retraction mechanism is activated inside the body Operators control the speed of needle retraction into the barrel Auto-Disable features prevent product tampering or reuse Fully integrated safety features

17

Products

Proprietary Safety Syringe Portfolio

Plastic for vial Glass ready-to-fill Insulin, TB and Safe Clinical Range 3 & 5mL Unifill™ syringe Fixed needle Unifill™ Select Attachable needles US production Pipeline Industrialisation Program Pipeline

18

Unitract 1mL Syringes

Designed for healthcare facilities and for self-injection Approved for use in:

United States (FDA) Canada Europe (CE Mark) Australia

US production August 2009 Commercial release shortly Status

19

Pharmaceutical Market for Prefilled Syringes

50+ prefilled drugs and vaccines Benefits for healthcare workers:

Convenient dose accuracy Faster and reduced inventory

Benefits for pharmaceutical manufacturers:

Avoid drug wastage (overfill) Product differentiation

Benefits of Prefilled Syringes

20

Pharmaceutical Market for Prefilled Syringes

Indicative Consumption

• f Prefilled Syringes by

Pharmaceutical Company

Pfizer 3% J&J 1% Serono 1% Abbott 1%

Sanofi-aventis 28% Sanofi-pasteur 10% GSK 15% Novartis 9% Wyeth 6% Roche 7% Merck 6% Amgen 5% TEVA 5%

Others 2% Biogen-Idec 1%

Calculated by published average unit cost per dose of 50 drugs available in a prefilled syringe format where 2008 annual revenues have been disclosed by the pharmaceutical company. Note - some drugs are available in formats

• ther than a prefilled syringe.

Unilife has used available industry data and its own estimates to calculate the % of doses supplied in a prefilled syringe format. The cost / unit of some drugs vary depending upon the measured dosage.

20+ pharmaceutical participants US$1.5 billion market in 2009 3 billion prefilled syringes by 2012^

^ Greystone Associates. Prefilled Syringes. 2009

Indicative Market Use

• f Prefilled Syringes

21

Pharmaceutical Market for Prefilled Syringes

High barriers for market entry Few glass prefilled suppliers No integrated safety prefilled Use of ancillary safety products

Production & shipment costs Size hinders marketability

22

Ancillary Safety Products Attached onto Standard Prefilled Syringes

Pharmaceutical Market for Prefilled Syringes

Unifill syringe Ancillary Safety Products Attached onto Standard Prefilled Syringes

23

Primary drug container Fully integrated medical device Compatible with standard filling and packaging systems Per standard handling process Reduced industrial footprint 60% reduction packaging, shipment and storage costs

Unifill™ syringe

Key Industrial Advantages

24

Provides highest level of safety Fully compliant with legislation Strong market differentiation Extension of product lifecycles Minimal operator retraining Ideal for self-administration

Unifill™ syringe

Key Marketing Advantages

25

$33 million program Commenced July 2008 One-year ahead schedule Target completion late-2010 Aggressive ramp plan Product engineered for high- volume production

Unifill™ syringe

Industrialisation Program

26

Mikron engaged as automated assembly line supplier Proof of Principle for Unifill completed by Mikron at speeds equivalent to high-volume production Commercial line with 60m annual capacity by late-2010 Target capacity on completion 50% more than original High-volume line with 150m annual capacity in late-2011 Now a process rather than a technical challenge

Unifill™ syringe

De-risking the Industrialisation Program

27

Additional pharmaceutical market opportunities

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Anti-coagulants Vaccine Anti-Infectives Anti-inflammatory Hematology Multiple Sclerosis HGH Obstetrics Other Oncology

Market share of accumulated annual drug sales in therapeutic class / unit dose cost

Sanofi-aventis Sanofi-pasteur GSK Novartis Wyeth Roche Merck Amgen TEVA Pfizer J&J Serono Abbott Biogen-Idec Others

Calculated by published average unit cost per dose of 50 drugs available in a prefilled syringe format where 2008 annual revenues have been disclosed by the pharmaceutical company. Note - some drugs are available in formats other than a prefilled syringe. Unilife has used available industry data and its own estimates to calculate the % of doses supplied in a prefilled syringe format. The cost / unit of some drugs vary depending upon the measured dosage.

Unifill™ syringe

28

International patent filings underway Not tied to other product agreements Supplied with attachable needles Ready for injection Retracts needle up to 1½ inches Discussions with interested parties Ideallysuitedforusewithvaccines Designed for Intramuscular (IM) Injection Market

Unifill™ Select

29

Unifill™ Select

80% 80% 20% 20%

All Prefilled Therapeutic Markets (except vaccines) Vaccines Only

Indicative Market Use of Prefilled Syringes by Needle Fixture

Fixed Needle Attachable Needle

30

Unifill™ Select

Vaccines Vaccine sales to double to US$39 billion in 2013* 70% of vaccine doses now in prefilled syringe format^ Influenza the single largest prefilled syringe application^ 1 billion seasonal influenza vaccine doses made in 2009# 2009 global H1N1 vaccine capacity of 3 billion doses+

* Kalorama Information. Nov 2009 ^ Greystone Associates. Prefilled Syringes. May 2009 # IFPMA / WHO. Influenza Vaccine Demand and Supply. March 2009 + WHO. September 2009

31

2010 Business Priorities

Scheduled completion late- 2010 Installation of commercial assembly line Appoint additional suppliers with dual-source goal

Glass barrel Rubber seals

Complete Industrialisation Program

32

Finalise exclusivity list with sanofi-aventis Unifill ™ syringe

Supply agreements with sanofi-aventis Agreements with additional pharmaceutical companies

Unifill™ Select syringe Exploring other opportunities for industry collaboration Expand pharmaceutical relationships

2010 Business Priorities

33

2010 Business Priorities

Complete ageing studies Commercial release Discussions with several interested healthcare and pharmaceutical companies Opportunities for evaluations

Harm reduction market Healthcare outside the US

Commence Unitract 1mL Sales

34

Establish new global headquarters

2010 Business Priorities

Developing major new facility in Pennsylvania Meet anticipated market demand for Unifill™ syringes Financial support from Pennsylvania Government Announcement once development agreement finalised

35

A global exchange for global technology leaders ASX vs NASDAQ for Health Care Equipment Companies

Significantly higher PE ratio on NASDAQ Listed Companies: ASX (70) NASDAQ (200) Median market cap: ASX (A$14m) NASDAQ (US$178m)

Allow investment from those with restrictive trading policies New Ticker Codes: NASDAQ – UNIS ASX - UNS

List on NASDAQ

2010 Business Priorities

36

Shareholders can choose between trading:

Chess Depository Index (CDIs) on the ASX

Unilife Corporation Common Stock on NASDAQ CDIs exchangeable for common stock on a 6 for 1 basis Computershare can convert CDIs to common stock 24 hours to switch between CDIs and common stock No fees for switching between common stock and CDIs

Trading Options Post-NASDAQ

37

Key Upcoming Milestones

Commercial release of US-made Unitract™ 1mL syringes Completion of negotiations for Unifill™ exclusivity list Redomiciliation and listing on NASDAQ Open new global headquarters and production facility in PA Installation of Unifill™ commercial assembly line Completion of Unifill™ industrialisation program Agreements with additional pharmaceutical companies

38

Summary

US-based and (soon-to-be) NASDAQ listed business World-class team with strong industry credentials ISO- 13485 certified with FDA-registered production facilities Unifill™ syringe represents ‘disruptive technology’ World’s major prefilled buyer committed A$47m (pre-sales) Strong cash position, multiple funding & revenue streams Target revenues of A$400m+ beyond 2014